UPC (Universe Pharmaceuticals) YoY EBITDA Growth: 74.36% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

UPC Universe Pharmaceuticals Inc UPC
59 GF Score
Price $7.21
GF Value $2.80
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Universe Pharmaceuticals YoY EBITDA Growth?

Universe Pharmaceuticals UPC +27.98% 59 YoY EBITDA Growth is 74.36% as of Mar. 2026. GuruFocus rates UPC with a GF Score™ of 59/100 and a GF Value™ of $2.80 (Significantly Overvalued). The stock has 7 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Universe Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was 74.36%.

Universe Pharmaceuticals's EBITDA per Share for the six months ended in Mar. 2026 was $-2.13.

Universe Pharmaceuticals YoY EBITDA Growth Related Terms

Universe Pharmaceuticals YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Universe Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Universe Pharmaceuticals YoY EBITDA Growth Chart

Universe Pharmaceuticals Annual Data
Trend Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
YoY EBITDA Growth
Get a 7-Day Free Trial 60.55 -137.48 42.76 13.90 98.78

Universe Pharmaceuticals Semi-Annual Data
Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -326.57 78.23 96.28 99.96 74.36
UPC
59GF Score
Universe Pharmaceuticals Inc UPC
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Universe Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Universe Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Sep. 2025 is calculated as:

YoY EBITDA Growth (A: Sep. 2025 )
=(EBITDA per Share (A: Sep. 2025 )-EBITDA per Share (A: Sep. 2024 ))/ | EBITDA per Share (A: Sep. 2024 ) |
=(-6.41--525.5)/ | -525.5 |
=98.78 %

Universe Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(-2.126--8.293)/ | -8.293 |
=74.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 74.36% mean?
Universe Pharmaceuticals (UPC) has a YoY EBITDA Growth of 74.36% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Universe Pharmaceuticals and its competitors.
Is Universe Pharmaceuticals' YoY EBITDA Growth too high?
Universe Pharmaceuticals' current YoY EBITDA Growth is 74.36%. Overall, Universe Pharmaceuticals has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Universe Pharmaceuticals' YoY EBITDA Growth compare to NPHC and CBIH?
Universe Pharmaceuticals' YoY EBITDA Growth of 74.36% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Universe Pharmaceuticals and its competitors. Universe Pharmaceuticals's current YoY EBITDA Growth is 74.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universe Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Universe Pharmaceuticals (UPC) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.80, compared to a current price of $7.21 — trading 157.5% above its estimated fair value. The current YoY EBITDA Growth is 74.36%. Universe Pharmaceuticals' overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Universe Pharmaceuticals (UPC), the current YoY EBITDA Growth is 74.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Universe Pharmaceuticals (UPC) Overvalued in 2026?

Based on GuruFocus' analysis, Universe Pharmaceuticals stock appears to be overvalued. The current stock price of $7.21 is trading 157.5% above its estimated GF Value™ of $2.80. GuruFocus considers Universe Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for UPC:

  • YoY EBITDA Growth: 74.36%
  • GF Value™: $2.80 vs. price of $7.21 (157.5% above fair value)
  • GF Score™: 59/100 with 7 warning signs

No single metric tells the full story. See the UPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Universe Pharmaceuticals Business Description

Address 265 Jingjiu Avenue, Jinggangshan Economic & Technological Development Zone, Jiangxi, Ji’an, CHN, 343100
Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.
59GF Score

Get the complete analysis for UPC

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.21
Price
$2.80
GF Value